title: [Sensorineural hearing loss: New prospects for therapy].
abstract: The authors developed a pathogenetically sound rationale for the estimation of the therapeutic efficacy of milgamma and milgamma compositum used to treat patients presenting with neurosensory loss of hearing. The results of relevant studies are presented. It is concluded that the inclusion of these preparations in the combined treatment of patients with acute and progredient forms of chronic neurosensory deafness creates conditions for the stable positive clinical effect.
authors.forename: A M
authors.initials: AM
authors.lastname: Kornienko
authors.forename: R A
authors.initials: RA
authors.lastname: Kornienko
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use; D000284:Administration, Oral; D000368:Aged; D001299:Audiometry; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006309:Hearing / Q000187:drug effects / Q000502:physiology*; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy* / Q000503:physiopathology; D003639:Hearing Loss, Sudden / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008875:Middle Aged; D012189:Retrospective Studies; D013831:Thiamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D013831:Thiamine; C013835:benphothiamine